Exhibit 99.1
Waterdrop Inc. Announces Third Quarter 2023 Unaudited Financial Results
BEIJING, Dec. 7, 2023 /PRNewswire/Waterdrop Inc. (Waterdrop, the Company or we) (NYSE: WDH), a leading technology
platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the third quarter ended September 30, 2023.
Financial and Operational Highlights for the Third Quarter of 2023
|
|
|
High-quality business performance: For the third quarter of 2023, the first-year premiums (FYP)
generated through our insurance business amounted to RMB1,695.4 million (US$232.4 million), representing a decrease of 5.0% year over year. Our net operating revenue was RMB686.5 million (US$94.1 million), representing an increase of 1.1%
quarter over quarter. |
|
|
|
Positive operating cash flow: As of September 30, 2023, our cash and cash equivalents and short-term
investments balance amounted to RMB3,139.0 million (US$430.2 million). We continued to generate positive operating cash flow, and have cash outflow of investing and financing activities. |
|
|
|
Further expanded product offerings: As of September 30, 2023, we offered 1,253 insurance products cumulatively on
our platform, as compared with 1,050 as of June 30, 2023. In the third quarter of 2023, the FYP generated from critical illness insurance products accounted for 24.4% of overall FYP, up by 2.6 percentage points quarter-over-quarter.
|
|
|
|
As of September 30, 2023, around 445 million people cumulatively had donated an aggregate of approximately
RMB61.3 billion to over 3.03 million patients through Waterdrop Medical Crowdfunding. |
|
|
|
Solidifying market position in patient recruitment: As of September 30, 2023, we cumulatively enrolled more
than 6,000 patients into over 800 clinical trial programs through E-Find Platform. |
Mr. Peng Shen, Founder, Chairman, and Chief Executive Officer of Waterdrop, commented, We are pleased to report seven consecutive quarters of
profitability. Our net profit reached RMB36.3 million in the third quarter, representing a quarter-over-quarter growth of 67.4%. During the quarter, we continued to adhere to a high-quality development approach focusing on user value, and our
business performance stayed on track.
Amid market turbulence, our insurance business continued to provide our users with high-quality service through
multiple channels and innovative product offerings. During the quarter, we further strengthened content creation capability applying Artificial Intelligence Generated Content (AIGC) technologies and increased the number of new users by
20.1% year over year. In addition, we continued to improve service to existing users and sustained the quarterly policy renewal rate at above 90%.
We are
happy to announce that during this quarter we have completed the acquisition of 60% equity interest of Shenzhen Cunzhen Qiushi Technology Co., Ltd. and its subsidiaries (collectively, Cunzhen Qiushi, also known as
Shenlanbao). For the third quarter of 2023, the FYP generated through Shenlanbao amounted to RMB102.3 million (US$14.0 million), accounting for 6.0% of overall FYP.
The synergy with Shenlanbao greatly enhanced our overall capability in serving long-term insurance users. The FYP of long-term insurance policies generated
through our insurance business, including Waterdrop Insurance Marketplace and Shenlanbao Insurance Marketplace, reached RMB644.2 million during the quarter, accounting for 38.0% of overall FYP and representing a growth of 16.6% year over year.
In medical crowdfunding business, our Operational Transparency Committee continuously improved the transparency of fundraising activities.
Meanwhile, we took concrete steps to refine our consultant services, boosting the Net Promoter Score rated by patients to 70%. Valuing our users and their opinions, we held the first Open Day events for donor and patient representatives,
respectively, during which we had in-depth conversations with our users and received positive feedback.
E-Find Platform sustained a rapid development with a 60.7% year-over-year increase in its income. In the third quarter, we collaborated with 135 pharmaceutical companies and CROs and successfully enrolled more than
800 patients. Given our solid performance, we established partnerships with more world-renowned pharmaceuticals and deepened cooperation with existing customers. In total, we onboarded 90 new clinical trial programs during the quarter. We also
launched a patient management project in the field of chronic disease.
Looking forward, we will continue to leverage our advantages in big data and
technologies and further integrate our resources in domestic insurance and healthcare industries to create more value for our users.
1